Typical Western blotting pattern of human immunodeficiency virus type 1 (HIV-1) antibody ofcontrols and patients [R-P; reference serum positive for anti-HIV-I antibody, R-N; reference serum negative for anti-HIV-I antibody, H-(1); healthy control positive for anti-P25 antibody, SY; syphilis patient (S-6) positive for anti-P25 and anti-P55 antibodies, SLE-(1); SLE patient (LA/aCL negative) (N-9) positive for anti-P52 and anti-P68 antibodies, SLE-(2); SLE patient with aCL (C-2), positive for anti-P25 and anti-P52 antibodies]. and 4/23 (17%) aCLJLA-negative]. None of the subjects' sera that was reactive to HIV-1 and/or HTLV-1 viral proteins showed a typical reactive pattern diagnostic of true HIV-1 and/or HTLV-1.
Talal et al' reported that 22/61 patients with SLE were positive for p24 (synonymous with p25 in this paper) antibody and suggested that there was a close relation between HIV-1 and conserved idiotype antibody. They also found that anti-Sm antibody in this clinical setting showed cross-reaction with p24. Studies on small numbers of subjects revealed a frequency of 0-1 19 of the mutant allele in white populations.2 About 1-4% of the population therefore is assumed to be homozygous for that mutation. Several asymptomatic hymozygotes were identified in these studies. This finding raises questions about the pathogenic significance of MAD deficiency. Determination of allele frequency in larger numbers of subjects with various clinical conditions is required to provide specifics concerning the clinical importance of MAD deficiency. The C34-T mutation which seems to be one of the most common mutations of any gene in white populations is also of ethnological interest since it has not yet been found in the Asian gene pool. 2 The MaeII restriction analysis faces two major disadvantages: first of all, this enzyme is expensive. Secondly, it is only sufficiently active under specific assay conditions. The reaction sample after PCR cannot be modified to allow the direct digestion with MaeII. Instead, the PCR product must be precipitated and resuspended in the MaeII assay buffer.
Therefore, a new method for detection of the C34-T mutation is presented that is both less expensive and less time consuming. DNA is extracted from blood by standard procedures. Exon 2 and part of intron 2 of the AMPD1 gene are amplified by PCR using two 18mer primers. The upper primer P1 starts in intron 1 and ends at the second to last nucleotide of exon 2. It corresponds to the wild type AMPD1 gene3 with the exception of the second to last nucleotide which is C instead ofA (5'-CATACAGCTG-AAGAGACA-3'). After amplification of the mutant allele, the PCR product contains the sequence ACATGT at the exon 2 -intron 2 boundary which represents a NspI restriction site. This NspI site is not present after amplification of the wild type allele. The lower primer P2 starts at the 83rd nucleotide of intron 2 (5'-AACACTGCTGAAAAATAG-3D. 
